Taking a daily multivitamin for two years produced a modest reduction in markers of biological ageing in older adults, a randomized trial found, prompting renewed questions about the role of multivitamins aging research in public health guidance.
Multivitamins Aging: What did the trial actually measure?
Verified facts: The trial enrolled 958 healthy participants with an average chronological age of about 70. Participants were randomly assigned to one of four pill regimens: a multivitamin with cocoa extract, a multivitamin alone, cocoa extract alone, or two placebos. Blood samples collected at baseline, one year and two years were analysed using five measures of DNA methylation known as epigenetic clocks. Howard Sesso, associate director of preventive medicine at Brigham and Women’s Hospital and Harvard Medical School and the study’s senior author, is listed among the investigators. The findings were published in the journal Nature Medicine as part of the COcoa Supplement and Multivitamin Outcomes Study (COSMOS).
Key measurable outcome: after accounting for age, sex and baseline measures, participants assigned to a daily multivitamin showed a slowdown on two of the five epigenetic clocks, specifically the clocks used to estimate mortality risk. The net effect equated to roughly four months less biological ageing over the two-year trial period. The cocoa extract did not affect any of the five clocks and did not change the multivitamin result.
Who benefited and what do the results imply?
Verified facts: The trial team observed that effects were larger among participants who showed signs of accelerated biological ageing at the study start. The investigators noted that nutritional status may partly explain this differential, suggesting participants with greater nutritional deficits at baseline experienced larger clock slowdowns. The authors cautioned that it is critical to determine the clinical relevance of these epigenetic changes and whether they translate into meaningful health benefits.
Analysis: Measured against the trial’s own endpoints, the result is constrained and specific. The change—two epigenetic clocks moving in a favourable direction—was measurable but small when expressed as months of biological time over two years. The improvement concentrated in biomarkers tied to mortality risk, but the trial did not measure downstream clinical events as primary outcomes for this biomarker analysis. That leaves a gap between a statistically detectable change in DNA methylation patterns and clear evidence of reduced disease incidence or extended healthy lifespan.
Accountability and context: the trial’s design, randomization and repeated biomarker sampling strengthen internal validity for the epigenetic outcomes reported. The investigators and journal publication explicitly call for further investigation to determine whether the modest epigenetic shifts observed will produce tangible clinical benefit for older adults. Howard Sesso emphasized that these results do not imply all older adults must begin taking a multivitamin, and that benefit may be concentrated among those with accelerated biological ageing at baseline.
Forward look: To move from biomarker change to public-health guidance will require trials designed to link epigenetic-clock modulation to concrete health outcomes, and analyses that clarify which subgroups—if any—derive clinically meaningful benefit. The current COSMOS subset provides a focused signal that merits targeted follow-up rather than broad policy shifts.
Final assessment: The randomized evidence shows a small, reproducible effect on measures of biological ageing from daily multivitamin use in older adults. That signal invites more targeted research to determine whether the biomarker gains reported translate into longer periods of healthy life and whether specific populations should be advised to consider multivitamins as part of preventive care for multivitamins aging.
